Cartesian Therapeutics Inc. (RNAC) Stock Forecast & Price Target
Cartesian Therapeutics Inc. · NASDAQ
$7.78-0.10 (-1.27%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Cartesian Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $16.00 to $44.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $32.60 sits 319% above the current $7.78. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.69 next quarter toward $-2.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Cartesian Therapeutics Inc.
As of Jul, 5 of 5 firms rate RNAC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RNAC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-0.69 – $-0.69 · 1 analysts · -6% YoY
Next period, 1 analysts expect Cartesian Therapeutics Inc. to earn $-0.69 a share (range $-0.69 – $-0.69), versus $-0.73 a year earlier. Full-year consensus is $-3.35, growing to $-2.68 the year after.
REVENUE · NEXT QUARTER
$161.1K
Range $0 – $500.0K · 1 analysts · -64% YoY
Revenue is expected to reach $161.1K (range $0 – $500.0K), -64.3% year-over-year. Full-year consensus is $552.3K, rising to $401.5K next year.
Top analysts covering Cartesian Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNAC.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$16.00+105.7% to target
Overall win rate
38%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$25.00+221.3% to target
Overall win rate
34%
+ Follow
#3
Gil Blum
Needham · Rank #298
Buy
$40.00+414.1% to target
Overall win rate
24%
+ Follow
#4
MF
Martin Fan
Wedbush
Buy
$38.00+388.4% to target
Coverage
—
+ Follow
#5
Julian Harrison
BTIG
Buy
$44.00+465.6% to target
Coverage
—
+ Follow
RNAC stock forecast FAQ
What is RNAC's average 12-month price target?+
The 5 analysts with a live target average $32.60 for Cartesian Therapeutics Inc. over the next 12 months, ranging from a $44.00 high to a $16.00 low.
Is RNAC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RNAC?+
The Street-high target is $44.00 (BTIG), and the Street-low is $16.00 (Cantor Fitzgerald). The average of all 5 active targets is $32.60.
How many Wall Street analysts cover RNAC?+
5 analysts have an active rating on Cartesian Therapeutics Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering RNAC?+
Among analysts who currently cover RNAC, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $16.00 target.
What is Cartesian Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-0.69 – $-0.69) across 1 analysts. Full-year EPS is projected at $-3.35, rising to $-2.68 the following year.
How much revenue is Cartesian Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $161.1K (range $0 – $500.0K). Full-year revenue is projected at $552.3K, growing to $401.5K next year.
Have analysts been upgrading or downgrading RNAC lately?+
As of Jul, 5 of 5 firms rate RNAC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNAC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
